Detection of Tumor DNA in Blood Samples From Cancer Patients

Phase

N/A

Condition

Neoplasms

Cancer

Treatment

N/A

Clinical Study ID

NCT02288754

LB1985106

Ages > 18
All Genders
Accepts Healthy Volunteers

Study Summary

The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is either commencing, currently undergoing or completed cytotoxic chemotherapy treatment. More generally, this approach will allow us to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age 18 years or older
Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas,ovary, prostate...) or stage II or III solid tumors undergoing curative surgery orneoadjuvant therapy followed by surgery
Starting treatment or a new line of treatment
Able to understand and grant informed consent
Able to have their blood drawn

Exclusion

Exclusion Criteria:

Unable to grant informed consent or comply with all study procedures.
Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia

Study Design

December 01, 2014

November 30, 2020

Connect with a study center

James Sinclair, MD
La Jolla, California 92037
United States
Site Not Available
Sharp Clinical Oncology Research
San Diego, California 92123
United States
Site Not Available
Cancer Care Associates
Torrance, California 90277
United States
Active - Recruiting
Summit Cancer Center
Post Falls, Idaho 83854
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.